Silence Therapeutics (SLN) Corporate presentation summary

Strategic vision and technology

• Focus on silencing diseases using proprietary siRNA technology for precision medicines.

• Proven GalNAc siRNA platform enables potent, durable, and specific gene silencing with infrequent dosing.

• Strong and expanding intellectual property portfolio supports broad utility.

• Global operations with headquarters in London, R&D in Berlin, and US office in New Jersey.

Clinical pipeline and programs

• Four clinical-stage assets target large unmet needs in rare and cardiometabolic diseases.

• Divesiran for polycythemia vera (PV) shows best-in-class potential with robust efficacy and safety.

• SLN312 (ANGPTL3) demonstrates competitive profile for dyslipidemia with robust reductions and infrequent dosing.

• SLN365 (GPR146) and SLN098 (INHBE) show promising preclinical results for HoFH and obesity, respectively.

Key clinical results and milestones

• Divesiran met primary endpoint in Phase 2 SANRECO trial: 88% response vs. 19% placebo (p<0.0001).

• Divesiran reduced phlebotomy need and improved hematocrit control, with favorable safety profile.

• SLN312 Phase 1 showed robust ANGPTL3 and lipid reductions, well tolerated with no major safety issues.

• SLN365 achieved >80% mRNA knockdown and significant cholesterol/triglyceride reductions in preclinical models.

• SLN098 demonstrated ~90% INHBE protein knockdown and reduced weight gain in preclinical studies.